Michael Ryskin
Stock Analyst at B of A Securities
(1.42)
# 3,346
Out of 4,876 analysts
36
Total ratings
47.83%
Success rate
-2.2%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $68 → $70 | $67.97 | +2.99% | 6 | Jun 25, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Buy | $9 → $8 | $2.41 | +232.64% | 3 | Mar 3, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $475 → $535 | $530.92 | +0.77% | 2 | Feb 4, 2025 | |
| ALGN Align Technology | Maintains: Underperform | $200 → $206 | $188.25 | +9.43% | 6 | Dec 13, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $50.88 | -21.38% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $5.65 | +68.29% | 1 | Jun 25, 2024 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $11.56 | +107.61% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $13.74 | +74.67% | 2 | Jul 31, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $156.67 | +14.89% | 7 | Nov 4, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $5.18 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $20.68 | +151.45% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $2.70 | +271.06% | 2 | Nov 10, 2021 |
Tempus AI
Jun 25, 2025
Maintains: Neutral
Price Target: $68 → $70
Current: $67.97
Upside: +2.99%
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.41
Upside: +232.64%
IDEXX Laboratories
Feb 4, 2025
Maintains: Neutral
Price Target: $475 → $535
Current: $530.92
Upside: +0.77%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200 → $206
Current: $188.25
Upside: +9.43%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $50.88
Upside: -21.38%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $5.65
Upside: +68.29%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $11.56
Upside: +107.61%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $13.74
Upside: +74.67%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $156.67
Upside: +14.89%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.18
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $20.68
Upside: +151.45%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $2.70
Upside: +271.06%